DNA methyltransferase 3B (DNMT3B) mediates gene silencing via epigenetic mechanisms during hepatocellular carcinoma (HCC) progression. We aimed to identify novel targets of DNMT3B and their potential regulatory mechanisms in HCC. Metastasis suppressor 1 (MTSS1) was one of the DNMT3B targets and selected for further study. DNMT3B overexpression was detected in 81.25% of clinical HCC specimens and was negatively associated with MTSS1 in HCC cells and clinical samples. The underlying mechanism by which DNMT3B silences MTSS1 was studied using a combination of methylation-specific polymerase chain reaction (PCR) and bisulfite genome sequencing, chromatin immunoprecipitation-PCR and luciferase reporter assays. We found that the MTSS1 promoter region was sparsely methylated, and the methylation inhibitors failed to abolish DNMT3B-mediated MTSS1 silencing. DNMT3B protein bound directly to the 5 0 -flanking region (À865/À645) of the MTSS1 gene to inhibit its transcription. The functional role of MTSS1 was investigated using in vitro and in vivo tumorigenicity assays. As a result, MTSS1 exerted tumor suppressor effects and arrested cells in the G2/M phase, but not the G1/S phase of the cell cycle when it was depleted or overexpressed in HCC cells. Taken together, MTSS1, a novel target of DNMT3B, is repressed by DNMT3B via a DNA methylation-independent mechanism. MTSS1 was further characterized as a novel tumor suppressor gene in HCC. These findings highlight how DNMT3B regulates MTSS1, and such data may be useful for the development of new treatment options for HCC.
Introduction
Gene silencing via epigenetic alterations of promoter CpG islands is a common event in various human cancers, such as hepatocellular carcinoma (HCC). DNA methylation, which is catalyzed by DNA methyltransferases (DNMTs), is an important epigenetic modification Jones and Takai, 2001) . Alterations in DNA methylation are commonly associated with abnormalities in DNMT expression in human cancers (Robertson, 2001; Kanai and Hirohashi, 2007; McGarvey et al., 2007) . Three DNMTs, including DNMT1, DNMT3A and DNMT3B, are the enzymes responsible for DNA methylation in eukaryotic cells (Okano et al., 1998; Bestor, 2000) . DNMT1 is the 'maintenance' DNMT, and DNMT3A and DNMT3B show de novo DNA methylation activity in vitro (Okano et al., 1999) . Mouse studies have shown that both Dnmt3a and Dnmt3b are required for the establishment and maintenance of genomic methylation patterns and proper murine development (Bachman et al., 2001; Gowher and Jeltsch, 2002; Kaneda et al., 2004) . DNMT3A and DNMT3B are upregulated in certain types of hematological malignancies and solid tumors, including leukocythemia (Mizuno et al., 2001; Claus and Lubbert, 2003) , colorectal cancer Takeshima et al., 2006) , lung cancer, breast cancer (Girault et al., 2003; Shafiei et al., 2008) and HCC (Saito et al., 2002; Choi et al., 2003) . Specifically, DNMT3B contributes to oncogenic phenotypes (Linhart et al., 2007) and tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing (Wang et al., 2007) . Rhee et al. (2002) demonstrated that somatic cell knockouts of both DNMT3B and DNMT1 led to demethylation and re-expression of tumor suppressor genes (TSGs). Accumulating evidence suggests that DNMT3B plays a more important role than the other DNMT enzymes in CpG island hypermethylation in human cancers (Saito et al., 2001; Weisenberger et al., 2004) .
Overexpression of DNMT3B protein significantly contributes to elevated DNMTs' activity and gene hypermethylation in breast cancer cells (Roll et al., 2008) . In esophageal cancer, the decreased expression of p14ARF and p16INK4a is involved in DNMT3B overexpression (Simao et al., 2006) . In lung cancer cells, DNMT3B-mediated promoter methylation causes RECK gene silencing and promotes Ras-induced metastasis (Chang et al., 2006) . Overexpression of DNMTs is involved in hepatocarcinogenesis and the increased mRNA levels of DNMT3A and DNMT3B may be a predictor of poor survival (Oh et al., 2007) . Our previous study showed that DNMT3B knockdown led to the expression of various TSGs that contain CpG islands in their 5 0 regions (Xu et al., 2005) . This suggested that the epigenetic mechanism by which DNMT3B inactivates TSGs may be an important way in which TSGs are silenced in HCC. In HCC, the correlation between DNMTs' expression and the frequency of gene promoter methylation remains to be examined (Saito et al., 2002) . In this study, we found that DNMT3B suppressed metastasis suppressor 1 (MTSS1) expression by directly binding to the promoter region of MTSS1, rather than DNA methylation. Further studies showed that MTSS1, a novel TSG in HCC, could dramatically suppress tumorigenesis in vitro and in vivo. DNMT3B regulated TSGs independent of its catalytic activity, which was consistent with the insignificant change in MTSS1 promoter methylation status in DNMT3B-depleted cells. These studies also provided novel insight into the role of MTSS1 in hepatocarcinogenesis, which is crucial for the development of new strategies for HCC treatment.
Results
Increased expression of DNMT3B in HCC tissues DNMT3B mRNA expression in 32 HCC tumors and paired non-tumor liver tissues was examined by quantitative real-time polymerase chain reaction (qPCR). Compared to the paired non-tumor tissues, 81.25% (26/32) of HCC cases showed overexpression of DNMT3B (defined as greater than a twofold increase) ( Figure 1a ). The average fold change of DNMT3B was significantly higher in tumor tissues (11.67) than in non-tumor tissues (1.54) (P ¼ 0.0012, paired Student's t-test; Figure 1b ). Five HCC cell lines (SMMC-7721, PLC8024, Hep3B, HepG2 and Huh7) showed higher expression of DNMT3B compared to the LO2 normal liver cells and the QSG-7701 non-tumor hepatocyte cells (Figure 1c ). These data indicate that elevated expression of DNMT3B might play an important role in hepatocarcinogenesis.
Depletion of DNMT3B affects many cancer-related genes that contain CpG islands To investigate if epigenetic modification is a major mechanism by which DNMT3B regulates TSGs during carcinogenesis, cDNA microarrays were used to profile gene expression in DNMT3B knockdown cells, as reported previously (Xu et al., 2005) . The 88 upregulated genes contained CpG islands in their 5 0 regions and were considered TSGs based on their biological functions (Supplementary Figure S1) . One particular gene of interest, MTSS1, was selected for further investigation.
SMMC-7721 cells were transfected with a vector-based small interfering RNA (siRNA) against DNMT3B, and scrambled siRNA was used as a negative control (7721-siMT3B or 7721-scramble). The siRNA directed against DNMT3B specifically silenced DNMT3B, but not DNMT1 or DNMT3A (*Po0.05; Figure 1d ). MTSS1 mRNA expression was fivefold higher in 7721-siMT3B cells compared to 7721-scramble cells (*Po0.05; Figure 1e ). MTSS1 was downregulated by DNMT3B in a dose-dependent manner in PLC8024 cells following transient transfection with a DNMT3B construct (Figures 1f and g ). To examine the potential correlation between the expression of MTSS1 and DNMT3B, we first examined the expression level of MTSS1 by qPCR in the 32 paired HCC tumors and adjacent non-tumor tissues described above. The average fold change of MTSS1 was significantly lower in tumor tissues (1.28) than in non-tumor tissues (3.40) (P ¼ 0.037, paired Student's t-test; Figure 1h ). We further investigated the negative correlation between DNMT3B and MTSS1 in these clinical specimens. MTSS1 expression was reversely correlated with DNMT3B expression in these specimens (Pearson's correlation coefficient À0.315, P ¼ 0.011; Figure 1i ). In addition, we also checked the expressions of DNMT3B and MTSS1 in these clinical samples by RT-PCR. As a result, DNMT3B expression was increased, and MTSS1 expression was decreased, in the HCC tumors (Figure 1j , case nos. 2 and 3). Decreased DNMT3B expression and increased MTSS1 expression was also detected in tumor tissues (Figure 1j , case no. 6). These results indicate that MTSS1 expression may be negatively associated with DNMT3B expression in HCC samples, prompting us to further study the molecular circuitry established by DNMT3B and MTSS1.
MTSS1 has tumor-suppressing effects in vitro and in vivo PLC8024 cells, which show moderate MTSS1 mRNA and protein levels, were used to explore the tumorsuppressing role of MTSS1 (Figures 2a and b) . PLC8024 cells were stably transfected with a pSU-PER-MTSS1-siRNA expression construct or a pSU-PER-MTSS1-scramble construct that served as the control. MTSS1 expression was decreased in the two siMTSS1 transfectants (8024-siMTSS1 nos. 3 and 6) compared to the two scrambled siRNA transfectants (8024-siCTL nos. 2 and 4) (Figure 2c ). The tumorsuppressive effects of MTSS1 were assessed by cell growth assays, foci formation assays, colony formation in soft agar and tumor xenograft experiments. Knockdown of MTSS1 significantly increased the cell growth rates of 8024-siMTSS1 nos. 3 and 6 compared to 8024-siCTL nos. 2 and 4 (*Po0.05; Figure 2d ). The frequency of foci formation was significantly higher in 8024-siMTSS1 no. 3 cells compared to 8024-siCTL no. 2 cells (**Po0.01; Figure 2e ). In addition, the colony formation in soft agar was significantly increased in 8024-siMTSS1 no. 3 cells compared to 8024-siCTL no. 2 cells (**Po0.01; Figure 2f ).
To explore the tumor-suppressive effects of MTSS1 in vivo, nude mice were inoculated subcutaneously with Figure 3c ). Collectively, these data indicate that MTSS1 has strong tumor-suppressive effects both in vitro and in vivo.
MTSS1 delays cell cycle progression
The role of MTSS1 in cell cycle progression was examined to probe the mechanism of MTSS1 in the development of HCC. 8024-siCTL no. 2 and 8024-siMTSS1 nos. 3 and 6 cells were synchronized at G0/G1 (T0), and then released into the complete medium for 14 (T14), 20 (T20) or 36 (T36) h. After being released for 14 h, 29.0% of 8024-siCTL no. 2 cells entered the G2/M phase. However, 37.6% and 44.1% of 8024-siMTSS1 nos. 3 and 6 cells, respectively, progressed into the G2/M phase (arrows; Figures 4a and b) . Following a 20-h release, approximately half of the 8024-siMTSS1 nos. 3 and 6 cells had already progressed through the G2/M and entered the G0/G1 phase of the next cycle. However, 8024-siCTL no. 2 cells continued to accumulate at the G2/M phase (Figures 4a and b) . These data indicate that 8024-siMTSS1 nos. 3 and 6 cells progress faster than 8024-siCTL no. 2 cells through the cell cycle (Figures 4a and b) , suggesting that MTSS1 may delay cell cycle progression.
MTSS1 arrests cells at the G2/M phase, but not at the G1/S phase To further investigate the role of MTSS1 in cell cycle progression, untreated 8024-siCTL no. 2, 8024-siMTSS1 no. 3, 8024-siMTSS1 no. 6, 7703-V1, MTSS1-C2 and MTSS1-C3 cells were subjected to DNA content analysis by flow cytometry. As shown in Figures 5a and c, the percentages of cells at G2/M in 8024-siMTSS1 nos. 3 (21.33%; Po0.01) and 6 (23.90%; Po0.01) were significantly lower than in 8024-siCTL no. 2 (30.70%). The percentage of 7703-V1 cells at G2/M (17.11%) was lower than MTSS1-C2 (24.12%; Po0.01) and -C3 (22.31%; Po0.05) cells (Figures 5b and c ). There were no differences in the percentage of cells in the S phase among the three cell lines. These data suggest that MTSS1 arrests cells at the G2/M phase, but not the G1/S phase, of the cell cycle.
To confirm the effect of MTSS1 on G2/M arrest, we examined the dynamic expression of several cell cycle 
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DNMT3B regulates MTSS1 independent of promoter methylation Because DNMT3B is responsible for de novo methylation in mammalian development, we hypothesized that epigenetic modification may be involved in DNMT3B-induced MTSS1 silencing. Thus, the methylation status of the MTSS1 promoter region was evaluated by methylationspecific PCR. No significant methylation changes were observed between the 7721-siMT3B and the 7721-scramble cells (Figure 6a ). Following treatment with 5-aza-2 0 -deoxycytidine (5-Aza) and hydralazine, two well-known methylation inhibitors, MTSS1 expression was not restored in several HCC cell lines, including SMMC7721, HepG2 and PLC8024 (Figure 6b and Supplementary Figure S2a) . This result suggests that silencing of MTSS1 in HCC cell lines may not be due to promoter methylation. The methylation levels of 73 CpG sites within two upstream regions (À817BÀ630 bp and À420BÀ158 bp) and 51 CpG sites with the downstream region ( þ 357B þ 942bp) of the MTSS1 gene were examined in two groups of cells using bisulfite genome sequencing (Figure 6c and Supplementary Figure S2b ). There were no significant changes in methylation levels in the 7721-siMT3B or the 7721-scramble cells (P40.05), even at the predicted binding sites for the Olf-1, USF and Sp1 transcription factors. The methylation ratio of the 124 CpG sites in the MTSS1 promoter was 23.15% and 23.55% in the 7721-siMT3B and 7721-scramble cells, respectively. Collectively, these data suggest that DNMT3B-induced silencing of MTSS1 in SMMC-7721 cells is independent of DNMT3B DNA methyltransferase activity.
DNMT3B protein binds to the 5 0 upstream region (À864/ À645) of MTSS1 and suppresses MTSS1 transcription To explore how DNMT3B regulates MTSS1, a chromatin immunoprecipitation (ChIP-PCR) assay was utilized to test whether a physical interaction exists between DNMT3B protein and the promoter region of MTSS1. Using an antibody against DNMT3B, we pulled down DNMT3B-targeted DNA fragments and probed for seven fragments representing different MTSS1 promoter regions (À1634B þ 400 bp, GenBank accession number NC-000008.10; F1: À1070/À787; F2: À864/À645; F3: À664/ À372, F4: À410/À267; F5: À296/ þ 8; F6: À1634/ À1263; F7: þ 220/ þ 400) by PCR (Figure 6d ). Only the F2 fragment was detected by PCR in DNMT3B-ChIPed DNA (Figure 6d ). We next tested whether this interaction affects MTSS1 transcription. The F2 region of the MTSS1 promoter was inserted into the pGL3-basic reporter vector (pMTSS1-F2-pGL3). Luciferase activity was detected following co-transfection with pMTSS1-F2-pGL3 and either pcDNA3.1-DNMT3B or pcDNA3.1. The pGL3-basic and pGL3-vectors were included as negative and positive controls, respectively. As shown in Figure 6e , the luciferase activities of pMTSS1-F2-PGL3 were significantly decreased when it was co-transfected with pcDNA3.1-DNMT3B compared to pcDNA3.1 (*Po0.001). All these data suggested that DNMT3B suppressed MTSS1 transcription via binding to the 5 0 upstream region (À864/À645) of MTSS1 gene.
Discussion
Epigenetic gene silencing occurring through changes in the methylation pattern is a common hallmark of several cancers (Baylin et al., 1998; Esteller, 2008) and raises a number of unresolved questions. An early in vitro study using the colon carcinoma cell line HCT116 reported that DNMT3B interacts with DNMT1 to silence gene expression in human cancer cells (Rhee et al., 2002) . Recent studies have suggested that DNMT3B is required for tumor development (Beaulieu et al., 2002) . Furthermore, DNMT3B1 efficiently methylates the same set of genes in both tumor and non-tumor tissues, demonstrating that the de novo methylation activity of methyltransferase 3B is essential to gene silencing. It is unclear as to whether DNMT3B has inherent target specificity. In this study, increased DNMT3B mRNA expression was found in HCC tumor tissues compared to non-tumor tissues. Elevated DNMT3B levels were also found in HCC cell lines. Our previous work showed that suppression of DNMT3B in HCC cells induced the expression of numerous genes related to tumor formation and development (Xu et al., 2005) , reinforcing the concept that DNMT3B may function as a negative regulator of certain TSGs. Approximately 60% of target genes contained CpG islands in their 5 0 region, suggesting that DNMT3B may silence their expression via DNA methylation.
MTSS1 was first described as a potential metastasis suppressor in bladder cancer (Lee et al., 2002) , and its regulatory mechanism is still unknown. MTSS1 expression was considered to be methylation-dependent owing the presence of a CpG island in its 5 0 -flanking region (Utikal et al., 2006) . In contrast, we found that DNMT3B suppressed the expression of MTSS1, which is independent of significant changes in promoter methylation status. In addition, ChIP-PCR data suggested that DNMT3B directly binds to the MTSS1 promoter to regulate MTSS1 expression. DNMT3B possesses a catalytic domain at its C terminus and a transcription repressor domain at its N terminus. Through its N-terminal domain, DNMT3B transcriptionally represses gene expression by recruiting transcriptional co-repressors and chromatin remodeling enzymes in a methylation-independent manner (Rountree et al., 2000; Bachman et al., 2001) . Although MTSS1 is a target of DNMT3B, its promoter region is sparsely methylated, and its expression could not be induced by treatment with 5-Aza. These data suggest that DNMT3B represses MTSS1 expression via a DNA methylation-independent mechanism. One study found that 5-Aza-dC upregulated MTSS1 expression in bladder cancer cells (Utikal et al., 2006) , but a different group did not see the same effect of 5-Aza-dC on MTSS1 expression in T24, J82, SW170 or VMCub3 bladder cancer cells (Nixdorf et al., 2004) . Thus, MTSS1 expression is not completely independent of promoter methylation, even in the same type of cancer. These data support the hypothesis that DNMT3B directly binds to the promoter region (À864/À645) of MTSS1 to inhibit DNMT3B-mediated MTSS1 silencing in HCC H Fan et al represents the unmethylated CpG site; P1-P10, represents bisulfite sequencing of the MTSS1 promoter for random clones from 7721-siMT3B cells; and S1-S10, represents bisulfite sequencing of the MTSS1 promoter for random clones from 7721-scramble cells. The boxed regions show the schematic of transcription factor binding sites. (d) ChIP assay was performed in SMMC-7721 cells using a DNMT3B-specific antibody, followed by PCR amplification of seven individual fragments representing MTSS1 promoter regions (F1-F7). Chromatin (defined as 'Input') and DNA products immunoprecipitated by IgG were used as positive and negative controls, respectively. (e) Luciferase reporter assays showed the inhibitory effect of DNMT3B on MTSS1 transcription in Chinese hamster ovary cells. The F2 region of the MTSS1 promoter was cloned into the pGL3-basic reporter vector (pMTSS1-F2-PGL3). The pMTSS1-F2-PGL3 vector was co-transfected with DNMT3B cDNA (pcDNA3.1-DNMT3B) into Chinese hamster ovary cells and assayed for luciferase activity. Each transfection was performed in triplicate and normalized to the total number of cells in each transfection assay (*Po0.001, independent Student's t-test).
DNMT3B-mediated MTSS1 silencing in HCC H Fan et al transcription, and the suppression of MTSS1 expression by DNMT3B is independent of DNMT3B DNA methyltransferase activity. As a target of DNMT3B, MTSS1 plays an important role in tumor development by several proposed mechanisms. Numerous studies identified MTSS1 as a suppressor of metastasis (Nixdorf et al., 2004; Liu et al., 2010) . Overexpression of MTSS1 significantly suppresses invasion, migration and adherence, and also governs metastasis, in breast cancer cells (Parr and Jiang, 2009) . A recent study in HCC cells found that depletion of MTSS1 resulted in the inhibition of invasion, growth and metastasis in MHCC97H cells . MTSS1 may play a role in hepatocellular carcinogenesis as evidenced by the elevated expression of MTSS1 in HCC patients (Ma et al., 2007) . We found that MTSS1 has strong tumor-suppressing actions in vitro and in vivo. MTSS1 arrested cells at the G2/M phase, but not the G1/S phase of the cell cycle. Our studies provide new insights into the biological mechanism of MTSS1, its potential role in HCC progression and its ability to inhibit HCC tumorigenicity. However, the underlying mechanism by which MTSS1 promotes cell cycle arrest remains to be investigated.
Although the role of MTSS1 in tumor development is confirmed by diverse experimental evidence, little is known about the mechanisms beyond DNA methylation that underlie MTSS1 expression during tumor development in several cancer types. We found that overexpression of DNMT3B was detected in 81.25% of HCC patients, supporting the notion that elevated expression of DNMT3B may play a role in HCC tumorigenesis. We also found that suppression of MTSS1, a novel target of DNMT3B, is regulated independently of its DNA methylation status. These findings are useful in understanding how MTSS1 is regulated by DNMT3B and may be beneficial in the development of new treatment options for HCC.
Materials and methods
Tissue samples from patients and HCC cell lines In all, 32 HCC patients, who underwent hepatectomy for HCC at the Cancer Center of Sun Yat-Sen University (Guangzhou, China), were included in the study. Samples were approved by the Committees for Ethical Review of Research at Sun Yat-Sen University. The HCC cell lines (BEL-7402, PLC8024, Hep3B, Huh7, HepG2, QGY-7703 and SMMC-7721), the QSG-7701 non-tumor hepatocyte line and the LO2 immortalized normal human liver cell line were obtained from the Institute of Virology, Chinese Academy of Medical Sciences (Beijing, China).
Bisulfite treatment and promoter methylation analysis Genomic DNA was extracted from the cells using the phenol-chloroform method followed by bisulfite modification. Methylation-specific PCR and bisulfite genome sequencing were performed as described previously (Tao et al., 2002) . Bisulfite-treated genomic DNA from 7721-siMT3B and 7721-scramble cells was amplified using methylated and unmethylated MTSS1 primers as reported previously (Utikal et al., 2006) . Primers designed for MTSS1 methylation-specific PCR and bisulfite genome sequencing are listed in Supplementary  Table S1 . Cell lines were treated with 5-Aza or hydralazine (Sigma-Aldrich, St Louis, MO, USA) to determine whether demethylation could restore MTSS1 expression. Briefly, 1 Â 10 5 cells were treatment with 0, 50 and 100 mM of 5-Aza or 0, 10 and 20 mM of hydralazine for 3 days, changing the medium containing 5-Aza or hydralazine every 24 h.
Chromatin immunoprecipitation and ChIP-PCR
The ChIP experiments were performed using an EZ-Magna ChIP G kit (Upstate Biotechnology, Lake Placid, NY, USA) according to the method described previously . The primers used for the amplification of the precipitated DNA fragments are listed in Supplementary Table S2 .
Luciferase reporter assay Chinese hamster ovary cells were plated at a density of 5 Â 10 5 / 12-well plate and transfected with the MTSS1 promoter construct and the DNMT3B expression plasmid, or an empty vector, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Luciferase activity was determined 24 h after transfection with Dual-Glo luciferase system (Promega, Madison, WI, USA). All experiments were repeated three times.
Cell synchronization and DNA content analysis by flow cytometry Cells were incubated in completed Dulbecco's modified Eagle's medium containing 10% fetal bovine serum for the G0/G1 phase synchronization. When the cells reached 40% confluency, they were treated with mimosine (400 mM) for 12 h. After treatment, cells were released into the complete medium for different time courses and collected for DNA content analysis. Cells were harvested, washed with phosphate-buffered saline containing 1% fetal bovine serum and fixed in 70% ethanol at À20 1C. The cells were then washed twice with phosphatebuffered saline containing 1% fetal bovine serum and incubated in phosphate-buffered saline containing 0.02% Triton X-100, 0.1 mg/ml RNase (Sigma-Aldrich) and 10 mg/ml propidium iodide (Sigma-Aldrich) for 30 min at 37 1C. Cell cycle distribution was examined by flow cytometry using a FACScan flow cytometer (Becton Dickinson & Co., San Jose, CA, USA). The relative number of cells in each phase of the cell cycle was analyzed using the Modfit program (Verity Software House Inc., Topsham, ME, USA).
In vitro tumorigenicity assays For colony formation in soft agar, 5 Â 10 3 cells in 0.4% bacto agar were placed on top of a solidified layer of 0.6% bacto agar in six-well plates. Colonies consisting of more than 80 cells were counted after 3 weeks, and the data are expressed as the mean±s.d. of triplicate wells within the same experiment.
The foci formation assay was performed by seeding 1 Â 10 3 cells in a six-well plate. After 7 days, the surviving colonies (450 cells per colony) were counted following crystal violet (Invitrogen) staining. Triplicate independent experiments were performed.
Tumor xenograft mouse model
Approximately 2 Â 10 6 cells were injected subcutaneously into the right or left hind legs of 4-week-old nude mice (n ¼ 6). Tumor formation was monitored over a 4-week period, and the tumor volume was measured weekly and calculated by the following formula: V ¼ 0.5 Â L Â W 
